Isotine Plus- an ayurvedic eye drop receives WHO-GMP

In an important step towards solidifying its position as one of the top Ayurvedic businesses, Uttar Pradesh-based Jagat Pharma has received certification from the WHO-GMP (World Health Organisation - Good Manufacturing Practises) and the Certificate of Pharmaceutical Products (CoPP) for its ground-breaking product, the ayurvedic eye drops Isotine Plus.

This is the first time a WHO-GMP certificate and (CoPP) certificate have been awarded to an Ayurvedic eye drop produced in the nation. Today, Jagat Pharma stands out and has established itself as one of the select few Ayurvedic product production facilities to have attained this high standard.

With a proven track record of reversing cataract-induced vision impairment, Jagat Pharma's ayurvedic eye drops Isotine Plus have been used in clinical settings for 36 years. The complicated eye illnesses including Cataracts, Macular Degeneration, Myopia, Hypermetropia, Glaucoma, Diabetic Retinopathy, Retinitis Pigmentosa, etc. are treated using eye drops.

Some of the most unique ayurvedic ingredients used in the Isotine Plus ayurvedic eye drops include Chandan (Santalum album), Apamarg (Achyranthes aspera), Fennel (Foeniculum vulgare), Punarnava (Boerhaviadiffusa), Bhringaraj (Ecliptaprostrata), Arjuna (Terminalia arjuna), and Satva Pudina (Mentha piperita), to name a few.
“We are indeed elated to have been accredited by the WHO-GMP certification and CoPP Certificate, which is a hallmark of best manufacturing practices. Our aim has always been to continue advanced medicinal research and come up with products which will provide the best medical benefit to the maximum number of people. The World Health Organization recognizing our dedicated efforts is an encouragement for us to put even more focus on research and innovation,” said Dr Mandeep Singh Basu, Director of Jagat Pharma.

Isotine Plus eye drop has undergone clinical testing by Jagat Pharma in individuals with developing cataracts and other difficult eye conditions. Under the CTRI Registration No. CTRI/2021/01/030699 (registered on 22/01/2021), an open-label, comparative, multi-centric, two-arm, and interventional study was carried out. The 6-month experiment, which involved 70 patients, demonstrated a substantial improvement in cases with immature cataract and a drop in cataract grade (from grade II to grade I). It was determined that frequent, long-term usage of Isotine Plus eye drop is safe.

Jagat Pharma recently released the findings of a retrospective observational research on the usage of Isotine Plus ayurvedic eye drops that Prof. Yamini of Banaras Hindu University, Uttar Pradesh, undertook. Uncorrected distance visual acuity (UDVA) and uncorrected near visual acuity (UNVA) significantly improved after therapy with Isotine Plus, according to the research, which comprised 308 cataract patients treated between 2017 and 2019.